SEC Company Response from PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — Nov 1, 2017
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: Nov. 1, 2017 · CIK: 0001095981 · Accession: 0001564590-17-020860
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219967
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Re: Cytori Therapeutics, Inc. Registration Statement on Form S-1 Filed August 14, 2017 File No. 333-219967
Dear Mr. Jones:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Cytori Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on November 2, 2017, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter.
Very truly yours,
CYTORI THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm cytx-corresp.htm Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121 November 1, 2017 VIA EDGAR Tom Jones Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Cytori Therapeutics, Inc. Registration Statement on Form S-1 Filed August 14, 2017 File No. 333-219967 Dear Mr. Jones: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Cytori Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 5:00 P.M. Eastern Time on November 2, 2017, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter. Very truly yours, CYTORI THERAPEUTICS, INC. By: /s/ Tiago M. Girão Tiago M. Girão Chief Financial Officer cc:Cheston J. Larson, Esq., Latham & Watkins LLP Christopher G. Geissinger, Esq., Latham & Watkins LLP